COMMUNIQUÉS West-GlobeNewswire
-
Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio
13/07/2026 -
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
13/07/2026 -
First patient treated in Phase 2 A-TANGO trial for acute-on-chronic liver failure
13/07/2026 -
Autonomix Medical Strengthens Global Intellectual Property Position with New Neural Sensing Patent Grant
13/07/2026 -
Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease
13/07/2026 -
Bexorg Expands Leadership Team with Appointments of Bruce Car, Ph.D., as Chief Scientific Officer and Michael Fenn, Ph.D., as Chief Business Officer
13/07/2026 -
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit
13/07/2026 -
Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting
13/07/2026 -
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026
13/07/2026 -
Bavarian Nordic’s Chikungunya Vaccine Submitted for Regulatory Approval in Brazil
13/07/2026 -
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
13/07/2026 -
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
13/07/2026 -
Acentra Health Appoints Michael Kingston as Chief Digital & Information Officer to Lead Technology and AI Innovation
13/07/2026 -
Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress
13/07/2026 -
Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
13/07/2026 -
REPEAT - Grifols deaths and harm: Patient safety & options for accountability
13/07/2026 -
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial
13/07/2026 -
BrewDog Waterloo to Host England's Biggest Pub Watch Party for Blockbuster Semifinal
13/07/2026 -
Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial
13/07/2026
Pages